Evidence map›Paper›PMID 33054390›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2020

Epac1 (Exchange Protein Directly Activated by cAMP 1) Upregulates LOX-1 (Oxidized Low-Density Lipoprotein Receptor 1) to Promote Foam Cell Formation and Atherosclerosis Development.

William G Robichaux, Fang C Mei, Wenli Yang, Hui Wang, Hua Sun, Zhen Zhou, Dianna M Milewicz, Ba-Bie Teng, Xiaodong Cheng

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Characterization of TFIIE-regulated genes by transcriptome analysis.Turkish journal of biology = Turk biyoloji dergisi · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

William G RobichauxDepartment of Integrative Biology and Pharmacology (W.G.R., F.C.M., W.Y., H.W., X.C.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Fang C MeiDepartment of Integrative Biology and Pharmacology (W.G.R., F.C.M., W.Y., H.W., X.C.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Wenli YangDepartment of Integrative Biology and Pharmacology (W.G.R., F.C.M., W.Y., H.W., X.C.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Hui WangDepartment of Integrative Biology and Pharmacology (W.G.R., F.C.M., W.Y., H.W., X.C.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Hua SunBrown Foundation Institute of Molecular Medicine (W.G.R., F.C.M., W.Y., H.W., H.S., B.-B.T.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Zhen ZhouDivision of Medical Genetics, Department of Internal Medicine (Z.Z., D.M.M.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Dianna M MilewiczDivision of Medical Genetics, Department of Internal Medicine (Z.Z., D.M.M.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Ba-Bie TengBrown Foundation Institute of Molecular Medicine (W.G.R., F.C.M., W.Y., H.W., H.S., B.-B.T.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Xiaodong ChengDepartment of Integrative Biology and Pharmacology (W.G.R., F.C.M., W.Y., H.W., X.C.), McGovern Medical School, The University of Texas Health Science Center, Houston.
Brown Foundation · USThe University of Texas Health Science Center · US

Funding

Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and TherapeuticsR35GM122536 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHENG, XIAODONG · 2017 to 2021
$1.9M
NIGMS NIH HHS R35 GM122536
6 · The paper itself

Abstract

objectiveThe cAMP second messenger system, a major stress-response pathway, plays essential roles in normal cardiovascular functions and in pathogenesis of heart diseases. Here, we test the hypothesis that the Epac1 (exchange protein directly activated by cAMP 1) acts as a major downstream effector of cAMP signaling to promote atherogenesis and represents a novel therapeutic target. Approach and Results: To ascertain Epac1's function in atherosclerosis development, a triple knockout mouse model (

conclusionsOur study demonstrates a fundamental role of cAMP/Epac1 signaling in vascular remodeling by promoting ox-LDL uptake and foam cell formation during atherosclerosis lesion development. Therefore, Epac1 represents a promising, unexplored therapeutic target for atherosclerosis.

Indexed as

Plaque, AtheroscleroticAnimalsAorta, ThoracicAortic DiseasesAPOBEC-1 DeaminaseAtherosclerosisCyclic AMPDisease Models, AnimalDisease ProgressionFemaleFoam CellsGuanine Nucleotide Exchange FactorsHumansMaleMice, Inbred C57BLMice, KnockoutAPOBEC-1 DeaminaseApobec1 protein, mouseCyclic AMPEpac protein, mouseGuanine Nucleotide Exchange FactorsOlr1 protein, mouseReceptors, LDLScavenger Receptors, Class Eatherogenesisatherosclerosisfoam cellsmicesecond messenger system

Identifiers

PMID33054390
PMCPMC7831851
OpenAlexW3093376653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.